US FDA approves Dyax's Kalbitor for hereditary angioedema
This article was originally published in Scrip
Executive Summary
The US FDA has approved Dyax's first drug, Kalbitor (ecallantide), for acute attacks of hereditary angioedema (HAE) in patients aged 16 years and older. The company's Nasdaq share price jumped by more than 20%, to $4.25, on December 2nd on the news.